{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:58:18Z","timestamp":1794542298121,"version":"4.9.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lipid nanoparticles (LNPs) have shown great potential for mRNA delivery, with polyethylene glycol (PEG) lipids playing a critical role in modulating particle size, stability and biodistribution. However, most PEGylated LNPs induce anti-PEG antibodies, leading to hypersensitivity and diminished efficacy upon repeated administration. Here we report hydrophilic, nonionic and biodegradable poly(D, L-serine) (pDLS) lipids as PEG-lipid alternatives in LNP formulations. Through systematic structural screening, we identify optimal lipid architectures that yield colloidally stable pDLS-LNPs with high mRNA encapsulation and transfection efficiency. Compared to the clinically approved BNT162b2 formulation (ALC-LNP), pDLS-LNPs loaded with SARS-CoV-2 spike mRNA achieve superior mRNA delivery, and elicit robust cellular and humoral immune responses in mice, without inducing systemic toxicity. Notably, repeated dosing with pDLS-LNPs triggers minimal anti-pDLS IgM production, unlike PEG-based counterparts. Furthermore, pDLS-LNPs remain stable under frozen storage for over 6 months. These findings establish polypeptide-based pDLS-LNPs as promising, immunologically inert alternatives to PEGylated LNPs for safe and effective mRNA delivery.<\/jats:p>","DOI":"10.1038\/s41467-026-73698-6","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:36:55Z","timestamp":1780061815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Polypeptide-engineered lipid nanoparticles for mRNA delivery with limited immunogenicity"],"prefix":"10.1038","volume":"17","author":[{"given":"Jin-Yue","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-7408","authenticated-orcid":false,"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6320-2047","authenticated-orcid":false,"given":"Brandon Yi Loong","family":"Seow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithiyaa Bala","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Hao","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1871-5448","authenticated-orcid":false,"given":"Yi Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"73698_CR1","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1126\/science.abn7591","volume":"375","author":"A Muik","year":"2022","unstructured":"Muik, A. et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science 375, 678\u2013680 (2022).","journal-title":"Science"},{"key":"73698_CR2","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMc2210546","volume":"387","author":"P Qu","year":"2022","unstructured":"Qu, P. et al. Durability of booster mRNA vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 subvariants. N. Engl. J. Med. 387, 1329\u20131331 (2022).","journal-title":"N. Engl. J. Med."},{"key":"73698_CR3","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817\u2013838 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"73698_CR4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","volume":"23","author":"C Liu","year":"2023","unstructured":"Liu, C. et al. mRNA-based cancer therapeutics. Nat. Rev. Cancer 23, 526\u2013543 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"73698_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc7804","volume":"13","author":"C Hotz","year":"2021","unstructured":"Hotz, C. et al. Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci. Transl Med. 13, eabc7804 (2021).","journal-title":"Sci. Transl Med."},{"key":"73698_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","volume":"585","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 585, 107\u2013112 (2020).","journal-title":"Nature"},{"key":"73698_CR7","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41551-022-00989-w","volume":"7","author":"Y You","year":"2023","unstructured":"You, Y. et al. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nat. Biomed. Eng. 7, 887\u2013900 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"73698_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1126\/science.aay3638","volume":"371","author":"C Krienke","year":"2021","unstructured":"Krienke, C. et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science 371, 145\u2013153 (2021).","journal-title":"Science"},{"key":"73698_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41573-021-00355-6","volume":"21","author":"A Coll\u00e9n","year":"2022","unstructured":"Coll\u00e9n, A. et al. VEGFA mRNA for regenerative treatment of heart failure. Nat. Rev. Drug Discov. 21, 79\u201380 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"73698_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022).","journal-title":"Science"},{"key":"73698_CR11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","volume":"16","author":"JA Kulkarni","year":"2021","unstructured":"Kulkarni, J. A. et al. The current landscape of nucleic acid therapeutics. Nat. Nanotechnol. 16, 630\u2013643 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"73698_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/d41586-021-02483-w","volume":"597","author":"E Dolgin","year":"2021","unstructured":"Dolgin, E. The tangled history of mRNA vaccines. Nature 597, 318\u2013324 (2021).","journal-title":"Nature"},{"key":"73698_CR13","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1039\/D1CS00617G","volume":"51","author":"Y Xiao","year":"2022","unstructured":"Xiao, Y. et al. Emerging mRNA technologies: delivery strategies and biomedical applications. Chem. Soc. Rev. 51, 3828\u20133845 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"73698_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41565-020-0737-y","volume":"15","author":"MD Shin","year":"2020","unstructured":"Shin, M. D. et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nat. Nanotechnol. 15, 646\u2013655 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"73698_CR15","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/s41565-022-01174-5","volume":"17","author":"X Huang","year":"2022","unstructured":"Huang, X. et al. Nanotechnology-based strategies against SARS-CoV-2 variants. Nat. Nanotechnol. 17, 1027\u20131037 (2022).","journal-title":"Nat. Nanotechnol."},{"key":"73698_CR16","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"73698_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27493-0","volume":"12","author":"X Han","year":"2021","unstructured":"Han, X. et al. An ionizable lipid toolbox for RNA delivery. Nat. Commun. 12, 7233 (2021).","journal-title":"Nat. Commun."},{"key":"73698_CR18","doi-asserted-by":"publisher","first-page":"12181","DOI":"10.1021\/acs.chemrev.1c00244","volume":"121","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y., Sun, C., Wang, C., Jankovic, K. E. & Dong, Y. Lipids and lipid derivatives for RNA delivery. Chem. Rev. 121, 12181\u201312277 (2021).","journal-title":"Chem. Rev."},{"key":"73698_CR19","doi-asserted-by":"publisher","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","volume":"16","author":"Y Ju","year":"2022","unstructured":"Ju, Y. et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano 16, 11769\u201311780 (2022).","journal-title":"ACS Nano"},{"key":"73698_CR20","doi-asserted-by":"publisher","first-page":"6114","DOI":"10.1016\/j.vaccine.2022.08.024","volume":"40","author":"JM Carre\u00f1o","year":"2022","unstructured":"Carre\u00f1o, J. M. et al. mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations. Vaccine 40, 6114\u20136124 (2022).","journal-title":"Vaccine"},{"key":"73698_CR21","doi-asserted-by":"publisher","first-page":"8838","DOI":"10.3390\/ijms23168838","volume":"23","author":"G Guerrini","year":"2022","unstructured":"Guerrini, G. et al. Monitoring anti-PEG antibodies level upon repeated lipid nanoparticle-based COVID-19 vaccine administration. Int. J. Mol. Sci. 23, 8838 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"73698_CR22","doi-asserted-by":"publisher","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","volume":"15","author":"BM Chen","year":"2021","unstructured":"Chen, B. M., Cheng, T. L. & Roffler, S. R. Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies. ACS Nano 15, 14022\u201314048 (2021).","journal-title":"ACS Nano"},{"key":"73698_CR23","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1016\/j.vaccine.2023.06.009","volume":"41","author":"GT Kozma","year":"2023","unstructured":"Kozma, G. T. et al. Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: evidence for immunogenicity of PEG. Vaccine 41, 4561\u20134570 (2023).","journal-title":"Vaccine"},{"key":"73698_CR24","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.xphs.2023.11.001","volume":"113","author":"SA Gaballa","year":"2024","unstructured":"Gaballa, S. A. et al. Treatment-induced and pre-existing anti-PEG antibodies: prevalence, clinical implications, and future perspectives. J. Pharm. Sci. 113, 555\u2013578 (2024).","journal-title":"J. Pharm. Sci."},{"key":"73698_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46327-3","volume":"15","author":"AH Isaac","year":"2024","unstructured":"Isaac, A. H. et al. Impact of PEG sensitization on the efficacy of PEG hydrogel-mediated tissue engineering. Nat. Commun. 15, 3283 (2024).","journal-title":"Nat. Commun."},{"key":"73698_CR26","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.jaci.2021.04.002","volume":"147","author":"KA Risma","year":"2021","unstructured":"Risma, K. A. et al. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines. J. Allergy Clin. Immunol. 147, 2075\u20132082.e2 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"73698_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41577-022-00825-x","volume":"23","author":"Y Ju","year":"2023","unstructured":"Ju, Y., Carre\u00f1o, J. M., Simon, V., Dawson, K. & Krammer, F. Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines. Nat. Rev. Immunol. 23, 135\u2013136 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"73698_CR28","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41573-023-00859-3","volume":"23","author":"D Bitounis","year":"2024","unstructured":"Bitounis, D., Jacquinet, E., Rogers, M. A. & Amiji, M. M. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat. Rev. Drug Discov. 23, 281\u2013300 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"73698_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.biomaterials.2019.01.019","volume":"197","author":"MY Shen","year":"2019","unstructured":"Shen, M. Y. et al. Hierarchically targetable polysaccharide-coated solid lipid nanoparticles as an oral chemo\/thermotherapy delivery system for local treatment of colon cancer. Biomaterials 197, 86\u2013100 (2019).","journal-title":"Biomaterials"},{"key":"73698_CR30","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1021\/acs.nanolett.2c00349","volume":"22","author":"W Yang","year":"2022","unstructured":"Yang, W. et al. Nanoparticle surface engineering with heparosan polysaccharide reduces serum protein adsorption and enhances cellular uptake. Nano Lett. 22, 2103\u20132111 (2022).","journal-title":"Nano Lett."},{"key":"73698_CR31","doi-asserted-by":"publisher","first-page":"6288","DOI":"10.1002\/anie.200902672","volume":"49","author":"K Knop","year":"2010","unstructured":"Knop, K., Hoogenboom, R., Fischer, D. & Schubert, U. S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. 49, 6288\u20136308 (2010).","journal-title":"Angew. Chem. Int. Ed."},{"key":"73698_CR32","doi-asserted-by":"publisher","first-page":"eaaw9562","DOI":"10.1126\/sciadv.aaw9562","volume":"5","author":"B Li","year":"2019","unstructured":"Li, B. et al. Trimethylamine N-oxidederived zwitterionic polymers: a new class of ultralow fouling bioinspired materials. Sci. Adv. 5, eaaw9562 (2019).","journal-title":"Sci. Adv."},{"key":"73698_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jconrel.2013.12.007","volume":"176","author":"Y Li","year":"2014","unstructured":"Li, Y. et al. Enhanced endosomal\/lysosomal escape by distearoyl phosphoethanolaminepolycarboxybetaine lipid for systemic delivery of siRNA. J. Control. Release 176, 104\u2013114 (2014).","journal-title":"J. Control. Release"},{"key":"73698_CR34","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jconrel.2023.07.031","volume":"361","author":"M Berger","year":"2023","unstructured":"Berger, M. et al. Poly(vinyl pyrrolidone) derivatives as PEG alternatives for stealth, non-toxic and less immunogenic siRNA-containing lipoplex delivery. J. Control. Release 361, 87\u2013101 (2023).","journal-title":"J. Control. Release"},{"key":"73698_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120843","volume":"274","author":"MN Leiske","year":"2021","unstructured":"Leiske, M. N. et al. Interactions of core cross-linked poly(2-oxazoline) and poly(2-oxazine) micelles with immune cells in human blood. Biomaterials 274, 120843 (2021).","journal-title":"Biomaterials"},{"key":"73698_CR36","doi-asserted-by":"publisher","first-page":"2201193","DOI":"10.1002\/smll.202201993","volume":"18","author":"A Najer","year":"2022","unstructured":"Najer, A. et al. Block length-dependent protein fouling on poly(2-oxazoline)-based polymersomes: influence on macrophage association and circulation behavior. Small 18, 2201193 (2022).","journal-title":"Small"},{"key":"73698_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201904716","volume":"15","author":"S Bleher","year":"2019","unstructured":"Bleher, S. et al. Poly(sarcosine) surface modification imparts stealth-like properties to liposomes. Small 15, 1904716 (2019).","journal-title":"Small"},{"key":"73698_CR38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jconrel.2020.03.022","volume":"322","author":"K Son","year":"2020","unstructured":"Son, K. et al. Evasion of the accelerated blood clearance phenomenon by polysarcosine coating of liposomes. J. Control. Release 322, 209\u2013216 (2020).","journal-title":"J. Control. Release"},{"key":"73698_CR39","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1021\/jacs.7b13017","volume":"140","author":"Y Hou","year":"2018","unstructured":"Hou, Y. et al. Macrocyclization of interferon-poly(\u03b1-amino acid) conjugates significantly improves the tumor retention, penetration, and antitumor efficacy. J. Am. Chem. Soc. 140, 1170\u20131178 (2018).","journal-title":"J. Am. Chem. Soc."},{"key":"73698_CR40","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1021\/acscentsci.8b00548","volume":"5","author":"Y Hou","year":"2019","unstructured":"Hou, Y. et al. Therapeutic protein PEPylation: the helix of nonfouling synthetic polypeptides minimizes antidrug antibody generation. ACS Cent. Sci. 5, 229\u2013236 (2019).","journal-title":"ACS Cent. Sci."},{"key":"73698_CR41","doi-asserted-by":"publisher","first-page":"10634","DOI":"10.1021\/acsanm.0c01834","volume":"3","author":"SS Nogueira","year":"2020","unstructured":"Nogueira, S. S. et al. Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery. ACS Appl. Nano Mater. 3, 10634\u201310645 (2020).","journal-title":"ACS Appl. Nano Mater."},{"key":"73698_CR42","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1080\/15583724.2022.2106490","volume":"63","author":"A Higuchi","year":"2023","unstructured":"Higuchi, A. et al. Material design for next-generation mRNA vaccines using lipid nanoparticles. Polym. Rev. 63, 394\u2013436 (2023).","journal-title":"Polym. Rev."},{"key":"73698_CR43","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.progpolymsci.2013.10.008","volume":"39","author":"C Deng","year":"2014","unstructured":"Deng, C. et al. Functional polypeptide and hybrid materials: precision synthesis via \u03b1-amino acid N-carboxyanhydride polymerization and emerging biomedical applications. Prog. Polym. Sci. 39, 330\u2013364 (2014).","journal-title":"Prog. Polym. Sci."},{"key":"73698_CR44","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/toxsci\/42.2.152","volume":"42","author":"A Bendele","year":"1998","unstructured":"Bendele, A., Seely, J., Richey, C., Sennello, G. & Shopp, G. Renal tubular vacuolation in animals treated with polyethylene-glycolconjugated proteins. Toxicol. Sci. 42, 152\u2013157 (1998).","journal-title":"Toxicol. Sci."},{"key":"73698_CR45","doi-asserted-by":"publisher","first-page":"101738","DOI":"10.1016\/j.nantod.2022.101738","volume":"48","author":"X Yao","year":"2023","unstructured":"Yao, X., Qi, C., Sun, C., Huo, F. & Jiang, X. Poly(ethylene glycol) alternatives in biomedical applications. Nano Today 48, 101738 (2023).","journal-title":"Nano Today"},{"key":"73698_CR46","doi-asserted-by":"publisher","first-page":"5654","DOI":"10.1021\/acs.biomac.3c00649","volume":"24","author":"P Khunsuk","year":"2023","unstructured":"Khunsuk, P., Pongma, C., Palaga, T. & Hoven, V. P. Zwitterionic polymer-decorated lipid nanoparticles for mRNA delivery in mammalian cells. Biomacromolecules 24, 5654\u20135665 (2023).","journal-title":"Biomacromolecules"},{"key":"73698_CR47","doi-asserted-by":"publisher","first-page":"2304033","DOI":"10.1002\/adhm.202304033","volume":"13","author":"AJDS Sanchez","year":"2024","unstructured":"Sanchez, A. J. D. S. et al. Substituting poly(ethylene glycol) lipids with poly(2-ethyl-2-oxazoline) lipids improves lipid nanoparticle repeat dosing. Adv. Healthcare Mater. 13, 2304033 (2024).","journal-title":"Adv. Healthcare Mater."},{"key":"73698_CR48","first-page":"86","volume":"37","author":"DD Kang","year":"2024","unstructured":"Kang, D. D. et al. Engineering LNPs with polysarcosine lipids for mRNA delivery. Bioact. Mater. 37, 86\u201393 (2024).","journal-title":"Bioact. Mater."},{"key":"73698_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25581-9","volume":"12","author":"D Zhang","year":"2021","unstructured":"Zhang, D. et al. Bio-inspired poly-DL-serine materials resist the foreign-body response. Nat. Commun. 12, 5327 (2021).","journal-title":"Nat. Commun."},{"key":"73698_CR50","doi-asserted-by":"publisher","first-page":"18454","DOI":"10.1021\/acsami.0c22308","volume":"13","author":"Y Sun","year":"2021","unstructured":"Sun, Y., Liu, J., Li, Z., Wang, J. & Huang, Y. Nonionic and water-soluble poly(D\/L\u2011serine) as a promising biomedical polymer for cryopreservation. ACS Appl. Mater. Interfaces 13, 18454\u201318461 (2021).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"73698_CR51","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.polymer.2008.01.021","volume":"49","author":"J Lin","year":"2008","unstructured":"Lin, J. et al. Aggregate structure change induced by intramolecular helix-coil transition. Polymer 49, 1132\u20131136 (2008).","journal-title":"Polymer"},{"key":"73698_CR52","first-page":"719","volume":"112","author":"X Zhang","year":"2008","unstructured":"Zhang, X. et al. Effect of chain conformational change on micelle structures: Experimental studies and molecular dynamics simulations. J. Phys. Chem. B 112, 719\u2013723 (2008).","journal-title":"J. Phys. Chem. B"},{"key":"73698_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.polymer.2022.125499","volume":"263","author":"H Zhu","year":"2022","unstructured":"Zhu, H. et al. Flexibility, size and hydrophobicity of alkyl side groups in methoxy-poly (ethylene glycol)-polypeptide for the nano-assembly and thermo-sensitivity. Polymer 263, 125499 (2022).","journal-title":"Polymer"},{"key":"73698_CR54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1042\/bj2320033","volume":"232","author":"WH Evans","year":"1985","unstructured":"Evans, W. H. & Hardison, W. G. Phospholipid, cholesterol, polypeptide and glycoprotein composition of hepatic endosome subfractions. Biochem. J. 232, 33\u201336 (1985).","journal-title":"Biochem. J."},{"key":"73698_CR55","doi-asserted-by":"publisher","first-page":"12881","DOI":"10.1073\/pnas.1306529110","volume":"110","author":"CA Alabi","year":"2013","unstructured":"Alabi, C. A. et al. Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery. Proc. Natl. Acad. Sci. USA. 110, 12881\u201312886 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"73698_CR56","first-page":"1","volume":"17","author":"N Demaurex","year":"2002","unstructured":"Demaurex, N. pH Homeostasis of cellular organelles. News Physiol. Sci. 17, 1\u20135 (2002).","journal-title":"News Physiol. Sci."},{"key":"73698_CR57","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41577-018-0088-1","volume":"19","author":"SC Eisenbarth","year":"2019","unstructured":"Eisenbarth, S. C. Dendritic cell subsets in T cell programming: location dictates function. Nat. Rev. Immunol. 19, 89\u2013103 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"73698_CR58","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jim.2013.02.009","volume":"391","author":"M Jahnmatz","year":"2013","unstructured":"Jahnmatz, M. et al. Optimization of a human IgG B-cell ELISpot assay for the analysis of vaccine-induced B-cell. J. Immunol. Methods. 391, 50\u201359 (2013).","journal-title":"J. Immunol. Methods."},{"key":"73698_CR59","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41565-023-01404-4","volume":"18","author":"X Han","year":"2023","unstructured":"Han, X. et al. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. Nat. Nanotechnol. 18, 1105\u20131114 (2023).","journal-title":"Nat. Nanotechnol."},{"key":"73698_CR60","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/ni.2914","volume":"15","author":"GV Zuccarino-Catania","year":"2014","unstructured":"Zuccarino-Catania, G. V. et al. CD80 and PD-L2 define functionally distinct memory B cell subsets that are independent of antibody isotype. Nat. Immunol. 15, 631\u2013637 (2014).","journal-title":"Nat. Immunol."},{"key":"73698_CR61","doi-asserted-by":"publisher","first-page":"797","DOI":"10.4049\/jimmunol.1400749","volume":"193","author":"JJ Hong","year":"2014","unstructured":"Hong, J. J. et al. Early lymphoid responses and germinal center formation correlate with lower viral load set points and better prognosis of simian immunodeficiency virus infection. J. Immunol. 193, 797\u2013806 (2014).","journal-title":"J. Immunol."},{"key":"73698_CR62","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jconrel.2023.09.003","volume":"363","author":"G Miao","year":"2023","unstructured":"Miao, G. et al. Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients. J. Control. Release 363, 12\u201326 (2023).","journal-title":"J. Control. Release"},{"key":"73698_CR63","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"73698_CR64","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2107456","volume":"385","author":"RW Frenck","year":"2021","unstructured":"Frenck, R. W. et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N. Engl. J. Med. 385, 239\u2013250 (2021).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73698-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73698-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73698-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:01:52Z","timestamp":1784764912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73698-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73698"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73698-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.Y.Y., J.Y.Z., and J.H.G. filed a patent on pDLS and their use in the preparation of LNPs. The rest of the authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6986"}}